{"entity":{"id":"michael-berger","kind":"person","name":"Michael F. Berger","aka":[],"tldr":"Built MSK-IMPACT, the tumour sequencing test used on more than 100,000 patients and the first FDA-authorised hospital panel.","summary":"Michael Berger led the development of MSK-IMPACT, the hybrid-capture sequencing assay that profiles hundreds of cancer genes in every MSKCC patient and became the first laboratory-developed tumour panel authorised by the FDA. The 2017 Nature Medicine paper on 10,000 profiled patients showed how prospective clinical sequencing enables trial matching. He also co-developed MSK-ACCESS for ctDNA and OncoKB with Debyani Chakravarty.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Berger%20MF%5BAuthor%5D%20MSK-IMPACT"}],"tags":["genomics","precision-oncology","diagnostics"],"related":[],"cancers":[],"sections":[],"technologies":["cgp","liquid-biopsy","companion-diagnostic"],"targets":[],"drugs":["foundationone-cdx"],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-tcga-pancancer-atlas-cell-2018"],"journals":[],"dependsOn":[],"notes":[],"role":"Associate Director, Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center","institutionId":"mskcc","specialisms":["Clinical cancer genomics","Tumour sequencing assays","Computational biology","Precision oncology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Berger%20MF%5BAuthor%5D%20MSK-IMPACT"}],"papers":[{"title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","journal":"Nature Medicine","year":2017,"doi":"10.1038/nm.4333"},{"title":"Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): a hybridization capture-based next-generation sequencing clinical assay for solid tumor molecular oncology","journal":"Journal of Molecular Diagnostics","year":2015,"doi":"10.1016/j.jmoldx.2014.12.006"},{"title":"TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features","journal":"Cell","year":2018,"url":"https://doi.org/10.1016/j.cell.2018.03.022","doi":"10.1016/j.cell.2018.03.022"}]},"route":"/people/michael-berger/","neighbours":{"technology":[{"id":"companion-diagnostic","kind":"technology","name":"Companion diagnostics","route":"/technologies/companion-diagnostic/"},{"id":"cgp","kind":"technology","name":"Comprehensive genomic profiling","route":"/technologies/cgp/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"}],"drug":[{"id":"foundationone-cdx","kind":"drug","name":"FoundationOne CDx / Liquid CDx","route":"/drugs/foundationone-cdx/"}],"institution":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/"}],"paper":[{"id":"paper-tcga-pancancer-atlas-cell-2018","kind":"paper","name":"TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features","route":"/key-papers/paper-tcga-pancancer-atlas-cell-2018/"}]}}